Vemurafenib (PLX4032)
Modify Date: 2024-01-04 10:51:48
Vemurafenib (PLX4032) structure
|
Common Name | Vemurafenib (PLX4032) | ||
|---|---|---|---|---|
| CAS Number | 918504-65-1 | Molecular Weight | 489.922 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 711.4±70.0 °C at 760 mmHg | |
| Molecular Formula | C23H18ClF2N3O3S | Melting Point | 260-262 °C | |
| MSDS | N/A | Flash Point | 384.0±35.7 °C | |
Use of Vemurafenib (PLX4032)Vemurafenib is a novel and potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively. |
| Name | vemurafenib |
|---|---|
| Synonym | More Synonyms |
| Description | Vemurafenib is a novel and potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively. |
|---|---|
| Related Catalog | |
| Target |
B-RafV600E:31 nM (IC50) c-Raf-1:48 nM (IC50) |
| In Vitro | Vemurafenib (PLX4032) selectively blocks the RAF/MEK/ERK pathway in BRAF mutant cells[1]. RG7204 is a potent inhibitor of proliferation in those expressing RAFV600E but not BRAFWT in 17 melanoma cell lines. Vemurafenib (RG7204) induces MEK and ERK phosphorylation at high concentrations in CHL-1 cells[2]. Ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032[3]. |
| In Vivo | Vemurafenib (PLX4032, 20, 25, 75 mg/kg, p.o.) causes dose-dependent inhibition of tumor growth, with higher exposures resulting in tumor regression of BRAF mutant xenografts[1]. RG7204 (12.5, 25, and 75 mg/kg, p.o.) significantly inhibits tumor growth and induced tumor regression in mice bearing LOX tumor xenografts[2]. |
| Cell Assay | Briefly, cells are plated in 96-well microtiter plates at a density of 1,000 to 5,000 cells per well in a volume of 180 μL. For the assay, Vemurafenib (RG7204) is prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution are added to plates in duplicate. The plates are assayed for proliferation 6 days after the cells are plated according to the procedure. |
| Animal Admin | Athymic nude mice, are with ages 13 to 14 weeks, and weighing approximately 23 to 25 g. For the LOX xenografts, 2×106 cells in 0.2 mL of PBS are injected s.c. into the right lateral flank. Vemurafenib (RG7204), formulated as MBP, is suspended at the desired concentration as needed for each dose group in an aqueous vehicle containing 2% Klucel LF and adjusted to pH 4 with dilute HCl. Temozolomide is of 250-mg capsules. Capsules are opened and combined into one bulk supply. To prepare the stock dosing material, temozolomide is first dissolved in 100% DMSO followed by dilution with saline to form a final milky white suspension in 10% DMSO/90% saline (pH 3.4). |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 711.4±70.0 °C at 760 mmHg |
| Melting Point | 260-262 °C |
| Molecular Formula | C23H18ClF2N3O3S |
| Molecular Weight | 489.922 |
| Flash Point | 384.0±35.7 °C |
| Exact Mass | 489.072540 |
| PSA | 100.30000 |
| LogP | 4.26 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.653 |
| Storage condition | -20°C |
| HS Code | 2935009090 |
|---|
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
| N-(3-{[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)-1-propanesulfonamide |
| Zelboraf |
| 1-Propanesulfonamide, N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]- |
| Vemurafenib (PLX4032,RG7204) |
| N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide |
| N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide |
| PLX4032 |